Compare Intel Corp (INTC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs 10X Genomics Inc — how do they compare? Intel Corp trades at $109.09 (market cap $597.96B), while 10X Genomics Inc trades at $78.6 (market cap $9.92B). The key difference: Intel Corp is far larger — about 60.3× 10X Genomics Inc's market cap, and Intel Corp pays a 2.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and 10X Genomics Inc for 92 Days on average.
| INTC | TXG | |
|---|---|---|
Market Cap | $597.96B | $9.92B |
Volume | 82,330,296 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $140.94 | $97.74 |
52-Week Low | $33.62 | $11.48 |
Typical Hold Time | 116 Days | 92 Days |
Enterprise Value | $618.77B | $9.44B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 4.82% today but maintains a bullish technical outlook with strong 2026 performance. The stock has surged over 220% year-to-date, driven by AI momentum and foundry growth. Recent earnings beats and High-NA chipmaking progress signal operational improvement, though negative profitability metrics and high valuations present challenges. Technical indicators show bullish momentum with key support at $109.
Intel's turnaround story shows promise with foundry revenue growth and government support, but faces execution risks against dominant competitors. The stock trades near analyst consensus target of $111.72, offering modest upside potential. Key risks include competitive pressures, margin challenges, and high debt levels that could limit near-term shareholder returns.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
